Methods. A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. Susceptibility testing was by broth microdilution using CLSI 2018 breakpoints. CAZ-AVI was tested with a fixed concentration of 4 µg/mL avibactam. Meropenem nonsusceptibility prompted β-lactamase screening by PCR and sequencing.
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Eba, All 99.6% (7, 037) Background. The eradication rate of Helicobacter pylori as a standard therapy based on amoxicillin and clarithromycin, exhibits a decreasing trend. Alternative approaches have been explored, but there is still controversy in the regimen change and these do not provide a satisfactory substitute to the existing standard therapy. Thus, a novel and efficient H. pylori eradication regimen should be developed. Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids (S-GEN) are expected to supersede the standard therapy for H. pylori eradication. In the previous study, we synthesized S-GEN complexes as a novel therapeutic agent. In a murine model, S-GEN released gentamicin to the gastric wall stably and the therapeutic effect was not inferior to the conventional standard therapy. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains.
Methods. The H. pylori strains were collected via endoscopic biopsy from 1,422 patients at Gangnam Severance Hospital in Seoul, Korea, between March 2015 and February 2018. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations.
Results. Finally, 140 H. pylori strains were analyzed in this study. The resistance rate to clarithromycin was 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC 50 Methods. This retrospective cohort used national VA data of veterans with SCI/D and active CRE infection (per documentation in the health record) from 2011 to 2013. CRE was defined as resistant to a carbapenem and third-generation cephalosporin. Antibiotics were described by empiric/definitive and monotherapy/combination therapy. Clinical outcomes included clinical failure/improvement, microbiological resolution, mortality and readmission in 30 days/1 year. SAS was used for analysis with significance at P ≤ 0.0125 due to multiple comparisons.
Results. Ninety-two CRE infections (62% K. pneumoniae) were identified in 87 patients, most often in urine cultures (58.7%). Carbapenems (20.7%) were used most frequently for CRE treatment. Combination therapy was used more often than monotherapy (empiric 56.3%, definitive 69.0%). Definitive combinations consisted of carbapenems/polymyxins (16.7%) or carbapenems/aminoglycosides (13.3%). Clinical outcomes for definitive monotherapy vs. combination, respectively, were: clinical failure (29.6% vs. 46.7%), improvement 1-10 days (48.2% vs. 33.3%), and 11-30 days (70.4% vs. 53.3%); microbiological resolution (48.2% vs. 38.3%); mortality at 30 days (22.2% vs. 30%), 90 days (22.2% vs. 41.7%), 1 year (25.9% vs. 51.7%) and readmission at 30 days (11.1% vs. 10%) and 1 year (37% vs. 30%). No significant differences in outcomes were identified for monotherapy vs. combination therapy or susceptible vs. nonsusceptible treatment.
Conclusion. For CRE treatment in the SCI/D population, carbapenems were the most widely used drug class; combination therapy was used most frequently. No improvements in clinical outcomes were found for combination therapy as either empiric or definitive treatment or for susceptible vs. nonsusceptible treatment.
Disclosures. All authors: No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Combination antimicrobial therapy is often recommended for the treatment of serious infections due to carbapenem-resistant Klebsiella pneumoniae (CRKP). Demonstrating synergy between ceftazidime-avibactam (C-A) and other antimicrobials in vitro may help elucidate the rate, magnitude, and duration of bactericidal activity and suggest combinations that may be effective in the clinical arena.
Synergistic Activity of Ceftazidime-Avibactam in Combination With
Methods. Three clinical CRKP were used for all experiments. C-A and polymyxin B (PB) MICs and time-kill analyses were performed in triplicate according to CLSI guidelines. Individual drugs were tested at ¼, ½, 1, 2, 4x MIC. A ≥3 log 10 CFU/mL reduction compared with the starting inoculum (10 6 ) was considered bactericidal. Synergy was assessed by testing combinations at the highest concentration of each drug that showed no activity alone and was defined as ≥2 log 10 CFU/mL increase in killing at 24 hours with the combination compared with most active agent alone.
Results. MICs: C-A 1, 8, 16 mg/L; PB 0.25, 0.25, 64 mg/L. C-A alone was bactericidal against all strains at 4× MIC (mean 24 hours bacterial reduction of 3.42 log 10 CFU/mL). PB at 4× MIC was bactericidal for all strains at 6 hours (mean bacterial reduction of 3.58 log 10 CFU/mL) but regrowth to control levels was seen at 24 hours. C-A alone at ½× MIC and combinations at ½× MIC for strains KPC1 and KPC2 yielded minimal killing followed by regrowth (mean 24 hours total bacterial count of 8.77 log 10 CFU/mL). In contrast, bactericidal activity was observed at 24h with C-A alone at ½× MIC and in combination at ½× MIC (3.14 and 3.62 log 10 CFU/mL reduction, respectively) for strain KPC3. Synergy was not observed for any isolate at the concentrations tested.
Conclusion. C-A demonstrated concentration-dependent bactericidal activity against all CRKP whereas PB showed initial bactericidality followed by regrowth and development of resistance. The combination of C-A and PB was not synergistic against C-A and PB susceptible or resistant CRKP isolates. Our data do not support the use of ceftazidime-avibactam in combination with polymyxin B for CRKP.
